Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.57 |
| ▸ | BRD2 | P25440 | 18/20 | 0.54 |
| ▸ | BRD3 | Q15059 | 12/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17627190 | 0.85 | BRD4 (0.64) | BRD4BRD2BRD3HDAC1HDAC7 | |
| SCHEMBL12095240 | 0.83 | BRD4 (0.58) | BRD4BRD2BRD3HDAC1HDAC7 | |
| SCHEMBL1907412 | 0.83 | BRD4 (0.53) | BRD4BRD2BRD3HDAC1HDAC7 | |
| SCHEMBL12095238 | 0.82 | BRD4 (0.59) | BRD4BRD2BRD3HDAC1HDAC7 | |
| SCHEMBL1904035 | 0.82 | BRD4 (0.60) | BRD4BRD2BRD3HDAC1HDAC7 | |
| SCHEMBL13723136 | 0.82 | BRD4 (0.66) | BRD4BRD2BRD3HDAC1HDAC7 | |
| SCHEMBL1907411 | 0.81 | BRD4 (0.52) | BRD4BRD2BRD3HDAC1HDAC7 | |
| SCHEMBL15450325 | 0.81 | BRD2 (0.58) | BRD4BRD2BRD3HDAC1HDAC7 | |
| SCHEMBL11980299 | 0.80 | BRD2 (0.71) | BRD4BRD2BRD3HDAC1HDAC7 | |
| SCHEMBL11908568 | 0.80 | BRD4 (0.56) | BRD4BRD2BRD3HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580957-B2 | Thetrahydroquinolines derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011054848-A1 | THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208814-A1 | Thetrahydroquinolines Derivatives As Bromodomain Inhibitors | BRD4, BRDT, BRPF3 | BRD4 1/4885BRD2 5/4885BRD3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.